source
- Intellia CRISPR drug succeeds in late-stage study against rare swelling disorderThe findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.BioPharma Dive · 3mo ago↗ source
- What’s the true risk for eating disorders with GLP-1s?The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning RoundsSTAT · 3mo ago↗ source
- Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much asEndpoints